Kobayashi in ¥500 billion buyout talks after red-yeast case
The preliminary, nonbinding offer could give shareholders a premium as Kobayashi seeks to recover from a supplement scandal and rising costs.
7 Articles
7 Articles
Kobayashi in $3.2 Billion Buyout Talks After Red-Yeast Case
Kobayashi Pharmaceutical Co., the Japanese health products company that was at the center of a supplement contamination scandal involving suspected deaths, is said to be considering a potential buyout offer of more than ¥500 billion ($3.2 billion) by private equity investors.
CVC, NSSK weigh $3.2bn Kobayashi Pharmaceutical take-private
PE firm CVC Capital Partners and Japanese investment firm Nippon Sangyo Suishin Kiko (NSSK) are considering a bid of more than JPY500bn ($3.2bn) to take Japanese healthcare products company Kobayashi Pharmaceutical private, according to a report by Bloomberg citing unnamed people familiar with the matter.
It has been revealed that Kobayashi Pharmaceutical is considering taking its shares private after receiving acquisition offers from the Japan Industrial Promotion Organization (NSSK) and UK-based CVC Capital Partners. The offers are presented as one of the options for increasing corporate value and are preliminary and not legally binding. Kobayashi Pharmaceutical commented, "It is true that we have received a joint offer, but we have not made an…
It was learned on the 24th that Kobayashi Pharmaceutical is considering taking its shares private. The company has received a tender offer (TOB) from an investment fund. If the privatization is realized, the fund will likely proceed with corporate governance reforms and management restructuring following the health problems caused by its red yeast rice supplement…
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
